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Recombinant human erythropoietin enhances vasoconstrictor
tone via endothelin-1 and constrictor prostanoids
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Recombinant human erythropoietin enhances vasoconstrictor tone via
endothelin-1 and constrictor prostanoids. Hypertension is the main side
effect developing in patients suffering from renal anemia who are treated
with recombinant human erythropoietin (rHuEPO). We investigated the
effect of rHuEPO on the vascular tone of isolated rabbit aorta and carotid
artery under isometric conditions. The production of prostacyclin and the
vasoconstrictor prostanoids PGF, and TXB2 was investigated in arterial
rings incubated with rHuEPO. Endothelial cells from human umbilical
veins (HUVECs) were isolated and cultured in flasks (37°C, 5% C02).
After incubation with rHuEPO, the formations of prostacyclin (as its
stable metabolite 6-keto-PGF1,,), PGF2, PGE2, thromboxane (TX) B2
and of ET-1 were measured by radioimmunoassays. rHuEPO had no
direct vasoconstrictor effect, but it enhanced noradrenalin-induced con-
tractions. This effect was more prominent in rings with intact endothelium
than in rings from which the endothelium had been mechanically re-
moved, indicating that endothelial vasoactivc factors might be involved.
Relaxations to acetyleholine (ACh, 1 jsM) were unaltered in the presence
or absence of rHuEPO, suggesting that the endothelial NO-cGMP
pathway was not impaired by rHuEPO. Incubation with rHuEPO (20 to
200 U/mI) increased the release of the vasoconstrictor mediators ET-1,
PGF2, and TXB,, and decreased prostacyclin formation in isolated rabbit
arterial rings and in HUVECs, respectively. The cyclooxygenase inhibitor
indomethacin abolished the rHuEPO-induced increase in vasoconstrictor
prostanoid production. ET-1 formation by HUVECs was also increased by
rHuEPO in a dose-dependent manner (maximal effect +90% by rHuEPO
200 U/mI, P < 0.05). Indomethacin and the selective ETA receptor
antagonist BQ123 each partly inhibited the enhancement of vascular
responsiveness to noradrenalin induced by rHuEPO in rabbit carotid
artery, but simultaneous administration of rHuEPO with both antagonists
completely abolished the force increment. In conclusion, these studies
show that a dose-dependent shift in the balance of constrictor and relaxing
prostanoids as well as an increased synthesis of ET-1 induced by rHuEPO
lead to the enhanced vascular responsiveness to noradrenalin in isolated
rabbit arteries. The increased vascular responsiveness to noradrenalin,
which is in line with clinical observations, may contribute to the hyperten-
sive side effect associated with rHuEPO therapy in patients with chronic
renal failure.
Recombinant human erythropoietin (rHuEPO) has been dem-
onstrated itt several studies to be effective in correcting the
anemia of chronic hemodialysis patients [1]. The main side effect
of rHuEPO treatment is the development or aggravation of
hypertension, which has been partially explained with a reversal of
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pre-existing hypoxic vasodilation, an increased peripheral vascular
resistance [2], a rise of blood viscosity [3], and an enhanced
cardiac output [4]. Samtleben et al [51 were the first to show that
the increase in blood pressure did not correlate with the rise in
hematocrit in all patients, suggesting that pressor mechanisms
other than the ones related to hematocrit and whole blood
viscosity may be involved. In addition, a direct vasoconstrictor
effect of rHuEPO on isolated renal and mesenteric resistance
vessels of normotensive Wistar-Kyoto rats has been shown in vitro
[6]. In a preliminary study, we found that rHuEPO potentiated the
vasoconstrictor effect of noradrenalin in isolated rabbit and
human arteries in vitro, and enhanced the release of ET-1 and
vasoconstrictor prostanoids from cultured human umbilical vein
endothelial cells [7]. Moreover, Carlini, Obialo and Rothstein [8]
recently demonstrated that cultured bovine pulmonary arterial
endothelial cells secrete endothelin-I (ET-1), a potent en-
dogenous vasoconstrictor peptide [9, 10], after incubation with
rHuEPO. These studies suggest that endothelial vasoconstrictor
autacoids might contribute to the hypertensive effect of rHuEPO.
Moreover, clinical studies demonstrated that plasma concentra-
tions of ET-1 were increased in patients on chronic hemodialysis
during rHuEPO therapy [8, 111. However, none of these studies
provided direct evidence of whether these vasoconstrictor medi-
ators are responsible for the vasoconstrictor effects of rHuEPO,
or if they are released secondary to rHuEPO-induced hyperten-
sion.
The availability of selective ET receptor antagonists allowed us
to further characterize the role of this vasoconstrictor peptide in
rHuEPO-induced vasoconstrictor tone. Therefore, in the present
study we investigated the effects of rHuEPO on vascular tone in
the isolated rabbit aorta, and the modulatory role of the intact
endothelium on these effects. The effect of rHuEPO on the
release of vasoactive prostanoids and ET-i was assessed using
incubation assays with rabbit aortic preparations, and the func-
tional role of ET-I and the prostanoids on vascular tone was
studied in the isolated rabbit carotid artery. The vascular wall of
this artery has been shown to contain endothelin A (ETA)
receptors [121, which mediate ET-i induced vasoconstriction via
inositol triphosphate-mediated calcium mobilization [13], and
which may be selectively blocked using the ETA receptor antag-
onist B0123 [14]. The contribution of vasoconstrictor prostanoids
was assessed in parallel experiments by blocking cyclooxygenase
activity with indomethacin. Cultured human umbilical vein endo-
thclial cells (HUVECs) were used to investigate whether human
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endothelial cells may be a source of ET-1 and constrictor pros-
tanoids after incubation with rHuEPO.
Methods
Organ bath experiments
New Zealand white rabbits were killed and exsanguinated, and
the aortas and common carotid arteries were removed and freed
of adhering connective and fatty tissue. Rings of thoracic aorta
were placed into organ baths filled with oxygenated modified
Krebs solution (95% 02, 5% C02, 37°C, pH 7,4) of the following
composition (mM): Na 145.0; K 5.95; Ca2 1.7; Mg2 1.2; Cl
128.15; HC03 25.0; H2 P04 1.2; S042 1.2; glucose 6.4; and
disodium EDTA, 0.025.
Isometric tension recording was performed as described else-
where [71. During 60 minutes the rings were gradually stretched to
a resting tension of 2 g, and repeatedly rinsed with fresh Krebs
solution. Then the rings were contracted by noradrenalin (NA, I
saM) and relaxed by acetyicholine (ACh, 1 tM) for testing of
endothelial integrity. Only rings relaxing by more than 70% of the
NA contraction plateau were included as endothelium-intact.
Rings on which the endothelium had been mechanically removed
showed no relaxation to ACh. After wash-out, a concentration-
response curve to NA (1 flM to 1 jkM) was recorded. After
wash-out and incubation with rHuEPO (200 U/ml; 30 mm) the
concentration-response curve was repeated. With control rings,
the second dose response curve was performed after 30 minutes
incubation in Krebs buffer. At the end of each experiment another
relaxation to ACh (1 /.LM) was induced.
Rings of rabbit common carotid arteries were used in an
identical experimental setting to elucidate the contribution of
ET-1 and prostanoids on rHuEPO-induced vasoconstrictor tone.
For this purpose, concentration-response curves to NA were
repeated after 30 minutes of incubation with rHuEPO alone, or in
the presence of the cyclooxygenase inhibitor indomethacin (10
or the ETA receptor antagonist BQ123 (10 .tM), or with
rHuEPO and both antagonists.
Incubation experiments with rabbit aortic rings
For incubation experiments, rings of rabbit aorta were placed
into organ baths (1.7 ml) filled with oxygenated Krebs buffer of
the above composition at 37°C. The bath medium was replaced
every 15 minutes with fresh Krebs solution. After an equilibration
period of two hours, a sample of the incubation medium was
collected for the determination of basal prostanoid release.
During the next 15 minute interval, rHuEPO (200 U/ml) was
added and the incubation medium collected for the determination
of rHuEPO-stimulated prostanoid production. Identical experi-
ments were performed with different aortic rings in the presence
of indomethacin (10 j.M). Samples were stored at —20°C until
assayed for prostanoid content by radioimmunoassay (RIA).
Cell culture experiments
Human umbilical vein endothelial cells were prepared and
cultivated as described previously [7, 15]. For the experiments
only cells of the first passage were used. For endothelin detection
cells grown to confluence in culture flasks (8 x 106 cells) were
washed three times with phosphate-buffered saline (PBS) of the
following composition (mM): Na 149.8; K 4.2; Mg2 0.5; Ca2
0.7; Cl— 141.9; HPO42 6.5; H2P04 1.5; glucose 5.6; pH 7.4.
Cells were incubated for one hour with PBS for the determination
of basal endothelin release, then they were incubated with PBS
containing 50, 100, or 200 U/mI rHuEPO for the determination of
stimulated endothelin release, or with vehicle (time controls), for
one hour. Preliminary experiments had revealed that this time was
sufficient to achieve a stable endothelin release. The incubation
medium (5 ml) was collected and kept frozen at —80°C until
analyzed by radioimmunoassay.
For the determination of prostaglandin release cells were
seeded on 6-well-plates and cultured until grown to confluence
(—1 X 10 cells/well). After three washings, they were incubated
for one hour with PBS for the determination of basal prostaglan-
din formation rates, then they were incubated with PBS contain-
ing 20, 50, 100, or 200 U/mI rHuEPO for the determination of
stimulated prostagiandin formation, or with vehicle (time con-
trols), for one hour. The incubation medium (1 ml) was collected
and frozen at —20°C until analyzed for prostagiandin content by
radioimmunoassays (RIA).
Radioimmunoassays
Concentrations of 6-keto-PGF1, PGF2, PGE2 and TXB2 in
the incubation media were measured by specific radioimmunoas-
says. The respective antibodies were from Sigma (Munich, Ger-
many), and the radiolabeled prostagiandins were from New
England Nuclear (Dreieich, Germany). The sensitivities of the
assays (detection limit defined as 10% displacement of tracer
binding) were 100 pg/mi for 6-keto-PGF1, 80 pg/mI for PGF2,
150 pg/mI for PGE2 and 40 pg/mi for TXB2. Endothelin-1 was
measured with a radioimmunoassay specific for endothelin-1
(Peninsula Lab. Inc., Belmont, CA, USA) after solid phase
extraction (SepPak C18 cartridges; Waters, Milford, CA, USA).
The absorbed peptides were eluted with 60% acetonitrile in 0.1%
TFA and dried in a centrifugal concentrator. The extracts were
reconstituted in 250 jid of assay buffer (0.1 M sodium phosphate,
0.05 M NaC1, 0.01% Triton X-100 and 0.01% sodium azide) and
assayed by RIA. The recovery of ET-1 was 87%. The detection
limit of the assay was 2 pg of immunoreactive ET-1/100 .tl of
sample. Cross reactivity of the antibody was 7% with endothelin-2,
and 17% with big endothelin.
Drugs
All drugs were purchased from Sigma, unless indicated differ-
ently. rHuEPO was a gift from Boehringer Mannheim, Germany.
Calculations and statistical analyses
All data are given as mean SEM. Differences in contraction
response in the presence or absence of rHuEPO were tested for
statistical significance using one-way analysis of variance followed
by Fisher's protected least-significant difference test.
EC5O values were calculated by using the logit transformation
according to Hafner, Heinen and Noack [16]. The EC5O values
were tested for statistical difference using the Student's 1-test for
unpaired data. Prostanoid and endothelin-1 synthesis in the
absence or presence of rHuEPO was compared with Student's
1-test for unpaired data. Significance was accepted at the 0.05 level
of probability.
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Fig. 1. Enhancement of noradrenalin-induced contractions of rabbit aortic
rings by incubation with rHuEPO (200 U/mI, 30 nsin). Symbols are: (0)
control fendothelium; (•) +endothcljum + rHuEPO; () control
—endothelium; (•) —endotheliuni + rHuEPO. Control rings were incu-
bated with vehicle for 30 minutes before the second concentration-
response curve to noradrenalin. Data are given as difterences in tension
between the first and second concentration-response curve to noradren-
aIm. Data are means SEM of 16 rings from 4 rabbits. *P < 0.05 between
rHuEPO-treated arid control rings.
Results
Fig. 2. Relaxations in response to acetylcholine (1 sM) of isolated rabbit
aortic rings with the endothelium preserved (+endothelium) or from which
the endothelium had been mechanically removed prior to the experiment
(—endothelium), in the presence or absence of rHuEPO. Relaxations are
expressed as percent of the contractile force induced by 1 /xM noradren-
aIm. Symbols are: () control; () rHuEPO.
Vasoconstrictor effects of rHuEPO
rHuEPO had no direct vasoconstrictor effects on rabbit aortic
rings in the concentration range from 20 to 200 U/mI, neither in
the presence nor in the absence of the endothelium. However,
when the concentration-response curve to noradrenalin was re-
peated after incubation of the aortic rings with rHuEPU (200
U/mi, 30 mm), the contractile response to noradrenalin was
significantly enhanced. As control preparations not incubated
with rHuEPO also showed a slight increase in tension when
exposed to a second dose-response curve of noradrenalin, the
increment in tension between the first and second dose-response
curves was compared between both groups (P < 0.05 at 1, 10, and
100 nM NA; Fig. 1). In rings where the endothelium had been
removed, the enhancement of rioradrenalin-induced contractions
was also present, though to a lesser extent (P < 0.05 at 1 and 10
flM NA). Endothelium-dependent relaxations to acetylchoiine
were not influenced by preincubation with rHuEPO (Fig. 2).
Prostanoid production by rabbit aortic rings
Basal formation of PGF2 in rabbit aortic rings (224.6 29.9
pg/ring 15 mm) was significantly stimulated by rHuEPO to
958.1 303.3 pg/ring 15 minutes (P < 0.05; N 13; Fig. 3). This
effect was significantly inhibited by 10 jiM indomethacin (255.0
87.2 pg/ring * 15 miii; P < 0.05 vs. rHuEPO). The release of TXB2
was significantly increased by rHuEPO from 78.5 11.3 to
106.6 17.4 pg/ring 15 minutes (P < 0.05; N = 13). Indometh-
acm significantly diminished this effect (to 62.2 5.2 pg/ring * 15
mm; P < 0,05 vs. rHuEPO; N = 13). In contrast, the formation of
Fig. 3. Effect of rHuEPO (200 U/mI) on prostanoid release by rabbit aortic
rings. Values are given as pg/ring and 15 minutes (means SEM of 10 to
13 rings from 4 rabbits). All prostanoid values were corrected for basal
release. Symbols are: (U) control; () rHuEPO; (2) rHuEPO + indo-
methacin. 'P < 0.05 versus control. 5P < 0.05 versus rHuEPO.
prostacyclin (measured as its stable hydrolysis product, 6-keto-
PGF1,) was reduced from 1704,1 462.1 pg/ring * 15 minutes to
1368.2 377.2 pg/ring * 15 minutes after rHuEPO (P < 0.05; N =
10). POE2 was only produced in minor amounts by rabbit aortic
rings and not altered by rFluEPO.
Contribution of prostanoids and endothelin-1 to vasoconstrictor
effect of rHuEPO in rabbit carotid artety
In isolated rabbit carotid artely, repetition of the concentra-
tiori-response curve to noradrenalin after incubation with
rHuEPO (200 U/mi, 30 miii) induced a significant increase in the
force increment as compared to controls, which was similar to the
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one observed in aortic rings (Fig. 4A). Both the cyclooxygenase
inhibitor indomethacin (10 ELM) and the endothelin A receptor
antagonist BQ 123, when given alone, partly diminished this force
increment (Fig. 4 A, B). Co-incubation of both indomethacin and
BQ 123 with rHuEPO completely abolished the rHuEPO-induced
force increment (Fig. 4C). The EC5O values for noradrenalin in
the presence or absence of rFIuEPO and the inhibitors indometh-
acm BQ 123, or both, are given in Table 1.
Effect of rHuEPO on endothelin-1 and prostanoid release in
cultured HUVECs
Incubation of HUVECS with increasing doses of rHuEPO (50
to 200 U/mI, 60 mm) induced a dose-dependent enhancement of
endothelin-1 release (P < 0.05; Fig. 5). Likewise, rHuEPO (20 to
200 U/mI) dose-dependently increased the release of PGF2a (P <
0.05 at 200 U/ml, Fig. 6A), whereas the formation of prostacyclin
was significantly reduced in the same dose range (P < 0.05, N =
Fig. 4. Noradrenalin-induced contractions of rabbit carotid arterial rings
after incubation with (A) rHuEPO (200 U/mI, 30 mm) or rHuEPO and
indomethacin (10 jrM), (B) rHuEPO or rHuEPO and BQ123 (10 pM),
and (C) rHuEPO or rHuEPO and indomethacin plus BQ123. Control
rings were incubated with vehicle for 30 minutes before the second
concentration-response curve to noradrenalin. Data are given as
differences in tension between the first and second concentration-
response curve to noradrenalin. Data are means SCM of 16 rings from
4 rabbits. Symbols in A are: (0) control; (•) rHuEPO; (A) rHuEPO +
indomethacin. Symbols in B are: (0) control; (S) rHuEPO; ()
rHuEPO + BQ123. Symbols in C are: (0) control; (S) rHuEPO; (E')
rHuEPO + indomethacin + BQ123. *p < 0.05 versus control rings.
tP < 0.05 versus rHuEPO.
Table 1. EC50 values for noradrenaline-induced contractions of isolated
rabbit carotid arterial rings in the presence or absence of rHuEPO,
rHuEPO + indomethacin, rHuEPO + the endothelin A receptor
antagonist BQ123, or both
EC50
mol/liter
P vs.
control
P vs.
rHuEPO
Control 44* 1o — 0.001
rHuEPO 77* i0 0.001 —
rHuEPO + indomethacin 1.3* i0 0.013 0.014
rHuEPO + BQ123
rHuEPO + Indo + BQ123
2.1* iO
1.5* 10—6
0.027
0.032
0.009
0.001
BC50 values were calculated according to the method of Hafner et al
[16] from 5 to 6 identical experiments in each group. Statistical signifi-
cance was calculated using Student's unpaired t-test.
8; Fig. 6B). PGE2 and TXB2 were only released in minor
concentrations by HUVECs and not measurably modulated by
incubation with rHuEPO (data not shown).
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Fig. 6. Release of (A) PGF2 and (B) 6-keto-PGF3 from HUVECs after
incubation with rHuEPO. Data are expressed as differences in prostanoid
release versus baseline. Values are means SEM of N = 5 to 7
experiments. 'P < 0.05 versus control.
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Fig. 5. Release of endothelin-l from cultured HUVEC after incubation with
rHuEPO. Data are expressed as differences in endothelin-1 release versus
baseline. Values are means SEM of N = 3 to 5 experiments. P < 0.05
versus control.
Discussion
The present study shows that rHuEPO significantly enhances
the contractile response to noradrenalin in rabbit aortic rings as
well as in rabbit carotid artery preparations. Incubation experi-
ments revealed that both endothelin-1 and the vasoconstrictor
prostanoids PGF2,, and TXB2 are involved in this effect. Both the
cyclooxygenase inhibitor indomethacin and the endothelin A
receptor antagonist BQ123 partly attenuated the increase in
contractile force induced by rHuEPO, and their combination
completely abolished this effect. The probable source of these
vasoconstrictor autacoids may be at least in part the endothelium,
since in arterial rings where the endothelium had been mechani-
cally removed the force increment induced by rHuEPO was
significantly attenuated. Furthermore, cultured HUVECs re-
leased significant amounts of ET-1 and PGF2,, in the presence of
increasing concentrations of rHuEPO.
Hypertension is one of the major side effects of rHuEPO
treatment in patients undergoing chronic hemodialysis. Although
several different mechanisms based upon the changes in hemato-
crit, whole blood viscosity, and cardiac performance induced by
rHuEPO have been postulated to be involved in this effect [2, 4,
171, it has evolved that rHuEPO-associated hypertension was not
strictly correlated to these hemorheological changes [5, 181. Thus,
the exact cause of this hypertensive action has not been fully
clarified. In our present study, rFIuEPO had no direct vasocon-
strictor effect on rabbit aorta (an elastic type artery), nor on rabbit
carotid artery (a muscular type artery). In contrast to this is the
finding by Heidenreich et al [6] of a direct vasoconstrictor effect of
rHuEPO in isolated arteriolar microvessels in vitro.
Recent studies have indicated possible links between rHuEPO-
associated hypertension and endothelium-derived vasoconstrictor
autacoids, mainly because of the fact that EPO receptors are
present on the surface of vascular endothelial cells [19], and that
these cells are capable of releasing ET-1 [9] and vasoconstrictor
*
prostanoids [20]. These observations have led to the suggestion
that ET-1 and/or vasoconstrictor prostanoids may be of patho-
genic importance in EPO-associated hypertension. In a prelimi-
nary publication we reported that rHuEPO (200 U/mi) induces
the release of ET-1 and TXB2 from HUVECs [7]. Our present
study extends these findings by demonstrating a clear concentra-
tion-response relationship for rHuEPO-induced release of these
vasoconstrictor autacoids from intact rabbit arterial rings and
cultured human endothelial cells, respectively. These effects could
already be observed at concentrations of rHuEPO which can be
achieved in plasma after intravenous rHuEPO administration
[21]. After subcutaneous administration, plasma concentrations
are substantially lower due to delayed absorption of the hormone.
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In accordance with these considerations is the clinical observation
that hypertension has more frequently been associated with
intravenous than with subcutaneous rHuEPO therapy [8, 18].
Additional experimental evidence for a possible role for ET-1 in
rHuEPO-associated increases in vascular tone has recently been
presented by Carlini Ct al [221, who found an increased ET-1
formation in cultured bovine pulmonary arterial endothelial cells
incubated with rHuEPO, and by Katoh et al [23], who presented
evidence for a direct EPO-induced release of ET-1 from isolated
perfused rat hindlimbs. However, it has remained unclear from
these studies whether the release of endothelial vasoconstrictor
mediators was responsible for the enhancement of vascular tone
by rHuEPO, or whether this was secondary to rHuEPO's vaso-
constrictor effects.
Our present results give direct evidence that ET-1 and vaso-
constrictor prostanoids do mediate the rHuEPO-induced en-
hancement of vascular tone, by demonstrating that inhibition of
either of these pathways partly diminished, and blockade of both
pathways completely abolished the the rHuEPO-induced force
increment in isolated rabbit carotid arterial rings.
There are several lines of evidence from our present study to
show that the endothelium is probably a major source for
rHuEPO-induced release of vasoconstrictor autacoids. Firstly,
although the contractile response to noradrenalin was enhanced
by rHuEPO in arterial rings with the endothelium present or
absent, this effect was more evident in rings with an intact
endothelial cell layer. Secondly, the relative change in autacoid
release after incubation with rHuEPO was similar in whole
arterial rings and in isolated cultured endothelial cells, respec-
tively.
The action of rHuEPO on the endothelium seems to be due to
a selective modulation of the ET-1 and the cyclooxygenase
pathways, but not all pathways by which the endothelium is able to
actively contribute to vascular tone. The prostanoid pathway was
obviously not affected at the phospholipase A2 or cyclooxygenase
level, which would have resulted in either inhibition or stimulation
of the whole array of prostanoids. The differential effects on
prostacyclin formation on the one hand, and the vasoconstrictor
prostanoids on the other hand, indicate that the net contribution
of prostanoids was even more in favor of vasoconstriction than the
changes in individual prostanoid concentrations might have sug-
gested. However, the sum effect of cyclooxygenase inhibition by
indomethacin resulted in a reduction of rHuEPO-induced vaso-
constrictor tone. The situation may even be more complex in viva,
as prostanoids can also be produced by non-endothelial cells
present in or adhering to the vascular wall, such as platelets and
leukocytes. rHuEPO has been shown to increase platelet aggre-
gability and thrombogenicity in vivo [24].
Another important endothelial vasodilator autacoid pathway,
the formation of nitric oxide (NO) from L-arginine [25], was not
involved in rHuEPO-induced vasoconstriction, as endothelium-
dependent, NO-mediated vasorelaxations induced by acetylcho-
line were not affected by rHuEPO in our model. It has been
suggested that inhibition of the NO-cGMP pathway may play a
more prominent role in rHuEPO-associated hypertension in viva,
as the rHuEPO-induced increase in hematocrit might contribute
to enhanced scavenging of NO by hemoglobin [26]. However,
ValIance, Benjamin and Collier [27] found no evidence that
increases in hematocrit by erythropoietin affect the intrinsic
modulation of vascular tone by NO. Del Castillo and coworkers
[28] recently presented additional evidence that three weeks of
subcutaneous rHuEPO administration significantly increased
blood pressure and hematocrit, and enhanced the urinary excre-
tion of nitrite and nitrate, metaholites of endogenous NO, in a rat
model in viva. They concluded that endogenous NO formation
was increased as a compensatory mechanism.
Our results showing an indirect vasoconstrictor effect of
rHuEPO, which evolves through the potentiation of noradrenalin-
mediated vasoconstriction, are in accordance with the clinical
observation of Berglund and Ekblom [17], who have shown an
increased systolic blood pressure during exercise in healthy men
treated with rHuEPO, indicating a significant enhancement of the
sympathotonic blood pressure reaction during rHuEPO therapy.
Hand and coworkers [29] reported that 12 weeks of treatment
with subcutaneous rHuEPO significantly increased the forearm
vasoconstrictor response to intraarterial noradrenalin in patients
with chronic renal failure. In this study no increase in ET-1 plasma
concentrations after rHuEPO therapy was found. However, an
unaltered plasma concentration of ET-1 with rHuEPO treatment
does not necessarily point to an unaltered endothelial ET-1
secretion rate, as 80% of ET-1 released from endothelial cells is
directed towards the vascular smooth muscle cells, and may thus
not appear in plasma [30, 31]. Takahashi et a! [11] reported that
intravenous administration of rHuEPO for eight weeks signifi-
cantly increased plasma ET-1 concentrations in hemodialysis
patients, and that the change in endothelin plasma concentration
was positively correlated with the change in mean blood pressure.
Carlini et al [8] found increased plasma concentrations of immu-
noreactive ET-1 in a group of hemodialysis patients receiving
intravenous rHuEPO, but not in those patients receiving subcu-
taneous rHuEPO. Increased concentrations of ET-1 may well
affect the vasoconstrictor response to noradrenalin, as low con-
centrations of ET-1 have been shown to potentiate contractions to
noradrenalin in isolated arterial rings [32], an observation that is
very similar to our present results with rHuEPO.
We conclude that rHuEPO indirectly enhances vasoconstrictor
tone in isolated rabbit arterial rings by potentiating the vasocon-
strictor effects of noradrenalin via endothelin-1 and vasoconstric-
tor prostanoids. Inhibition of either of these pathways partly
diminishes, and blockade of both completely abolishes rHuEPO-
induced increases in vasoconstrictor tone. These experimental
data may explain in part the increased blood pressure observed in
patients treated with rHuEPO in viva. Further studies using
cyclooxygenase inhibitors and endothelin A receptor antagonists,
respectively, may serve to characterize the functional role of these
mediators in rHuEPO-associated hypertension in patients with
chronic renal failure.
Repnnt requests to Dr. Stefanie M. Bode-Roger, Institute of Clinical
Pharmacology, 1-lannover Medical School, 30623 1-lannover, Germany.
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